SCHEMBL6911913

SCHEMBL6911913

CCC(=O)C(N1CCOCC1)S(=O)(=O)N1CCC(Oc2ccc(Cl)cn2)CC1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP1 P03956 1/20 0.51
FPR2 P25090 1/20 0.47
PROKR1 Q8TCW9 1/20 0.47
LIPE Q05469 1/20 0.37
TACR3 P29371 1/20 0.36
IP6K1 Q92551 1/20 0.36
HRH3 Q9Y5N1 4/20 0.36
TDO2 P48775 1/20 0.35
GPR119 Q8TDV5 1/20 0.35
CACNB4 O00305 3/20 0.35
CACNA1A O00555 3/20 0.35
CACNA1G O43497 3/20 0.35
CACNG3 O60359 3/20 0.35
CACNA1F O60840 3/20 0.35
CACNA1H O95180 3/20 0.35
CACNB3 P54284 3/20 0.35
CACNA2D1 P54289 3/20 0.35
CACNG7 P62955 3/20 0.35
CACNA1B Q00975 3/20 0.35
CACNA1D Q01668 3/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7023218 0.84 MMP1 (0.53) MMP1FPR2PROKR1LIPETACR3
SCHEMBL7018357 0.82 MMP1 (0.49) MMP1FPR2PROKR1LIPETACR3
SCHEMBL6021557 0.80 MMP1 (0.52) MMP1FPR2PROKR1LIPEIP6K1
SCHEMBL7020098 0.79 MMP1 (0.53) MMP1FPR2PROKR1LIPETACR3
SCHEMBL943749 0.76 MMP1 (0.56) MMP1FPR2PROKR1LIPETACR3
SCHEMBL943397 0.75 FPR2 (0.48) MMP1FPR2PROKR1LIPEHRH3
SCHEMBL941398 0.74 MMP1 (0.54) MMP1FPR2PROKR1LIPEIP6K1
SCHEMBL942627 0.74 FPR2 (0.47) MMP1FPR2PROKR1KMT2AALDH1A1
SCHEMBL940600 0.73 MMP1 (0.57) MMP1FPR2PROKR1LIPETACR3
SCHEMBL941502 0.73 FPR2 (0.64) MMP1FPR2PROKR1TACR3TDO2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040127528-A1 Metalloproteinase inhibitors ASTRAZENECA AB (SE) 2004-07-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040127528-A1 Metalloproteinase inhibitors MMP9, MMP10, MMP3 MMP1 17/4885FPR2 1510/4885PROKR1 2106/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.